Revenue Estimates Analysis: Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

The share price of the stock surged 135.46% for the year. Activist investor William Ackman of Pershing Square Capital Management has also cut his stake in the pharma company while CEO Joseph Papa's attempts to sell out its Salix unit to Takeda have also failed.

Hewlett Packard Enterprise Company (NYSE:HPE) traded 20.62 Million shares and was closed at $23.49 per share. Even as the company appointed a new CEO, who has strategized how Valeant would repay its obligations while revamping operations, the share price has dropped 85.25% so far this year. Boothbay Fund Management LLC now owns 7,632 shares of the specialty pharmaceutical company's stock worth $201,000 after buying an additional 5,599 shares during the last quarter. The stock appeared -88.24% below its 52-week highs and is up -8.54% for the last five trades. During its last trading session, Stock traded with the total exchanged volume of 16.6 million shares. This is beside the stock underperforming the broader market a year ago. The stock has a 50 day moving average of $21.55 and a 200 day moving average of $24.82. Of all the major health-care stocks to own in 2016, perhaps the worst to own has been Valeant Pharmaceuticals International Inc.

Valeant Pharmaceuticals International (NYSE:VRX) last posted its quarterly earnings results on Tuesday, November 8th.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) have shown a high EPS growth of 4.40% in the last 5 years and has earnings growth of N\A yoy. In contrast to the year ago quarter EPS was at 0. Analyst's mean target price for SWC is $17.66 while analysts mean recommendation is 2.30.

Many analysts are providing their Estimated Earnings analysis for Valeant Pharmaceuticals International, Inc. and for the current quarter 18 analysts have projected that the stock could give an Average Earnings estimate of $1.22/share.

Other equities research analysts also recently issued research reports about the company. Morgan Stanley reissued an "overweight" rating and issued a $42.00 price target on shares of Valeant Pharmaceuticals International in a research note on Friday, August 26th. The share price is trading in a range of $13.63 - 14.23.

The stock has a high price target of $12 according to consensus of 11 analysts. 13 advised the "Hold" rating about this stock.

When it comes to the Analysis of a Stock, Price Target plays a vital role. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company.

Number of analysts are covering this stock and now stock has got OUTPERFORM rating from no analyst of Thomson Reuters, 5 analysts given HOLD rating to the stock and 0 given UNDERPERFORM rating to Stillwater Mining Company (NYSE:SWC) stock.

Let's have a look at some of the important valuation ratios of the Valeant Pharmaceuticals International, Inc. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Related:

Comments


Other news